Document Detail


Immunomodulation in polytrauma and polymicrobial sepsis - where do we stand?
MedLine Citation:
PMID:  21158733     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Due to improved treatment strategies mortality in multiple trauma patients has been decreased over the last decades. However, posttraumatic complications like sepsis and subsequent multiple organ dysfunction syndrome (MODS) remain a major problem on intensive care units following major trauma. The clinical course after multiple trauma depends on the balance or imbalance of the pro- and anti-inflammatory immune response. The predominance of the proinflammatory response leads to the "Systemic Inflammatory Response Syndrome" (SIRS), whereas the "Compensatory Anti-inflammatory Response Syndrome" (CARS) might result in immune suppression with an enhanced risk for infectious complications. Both, SIRS and CARS, play a pivotal role in the development of sepsis and the "Multiple Organ Dysfunction Syndrome" (MODS). A gender dimorphism in the host response after multiple trauma and sepsis has already been described. In experimental as well as clinical studies, a protective effect of female sex hormones and precursors like androstenediol has been revealed. Moreover, blockade of androgen receptors and the inhibition of dihydrotestosterone (DHT) synthesis were shown to provide beneficial effects on the immune response. Beside sex hormones, modulation of the Toll Like Receptor (TLR) pathway by macrophage-activating lipopeptide-2 (MALP-2) has sufficiently been described. Furthermore, hydrogen sulfide (H₂S) and substance P have recently been revealed important for proinflammatory action in animal models of inflammation. Thus, these agents might be potential candidates for new treatment strategies in septic patients in order to improve the still unsatisfactory outcome of multiple trauma patients. If applicable, patents of each described agent are provided within the text.
Authors:
Claudia Neunaber; Christian Zeckey; Hagen Andruszkow; Michael Frink; Philipp Mommsen; Christian Krettek; Frank Hildebrand
Related Documents :
18084263 - Innate immunity as a driving force in renal disease.
17477023 - The role of proximal tubular cells in interstitial fibrosis: understanding tgf-beta1.
16418733 - Keratinocyte apoptosis in epidermal development and disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Recent patents on inflammation & allergy drug discovery     Volume:  5     ISSN:  1872-213X     ISO Abbreviation:  Recent Pat Inflamm Allergy Drug Discov     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-10     Completed Date:  2011-05-24     Revised Date:  2011-06-17    
Medline Journal Info:
Nlm Unique ID:  101309297     Medline TA:  Recent Pat Inflamm Allergy Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  17-25     Citation Subset:  IM    
Affiliation:
Trauma Department, Hannover Medical School, Hannover, Germany. neunaber.claudia@mh-hannover.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Androstenediol / therapeutic use
Animals
Dehydroepiandrosterone / therapeutic use
Finasteride / therapeutic use
Flutamide / therapeutic use
Humans
Immunomodulation*
Lipopeptides / therapeutic use
Multiple Trauma / drug therapy*,  immunology
Sepsis / drug therapy*,  immunology
Chemical
Reg. No./Substance:
0/Lipopeptides; 0/macrophage stimulatory lipopeptide 2; 13311-84-7/Flutamide; 521-17-5/Androstenediol; 53-43-0/Dehydroepiandrosterone; 98319-26-7/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Using insights into Pim1 structure to design new anticancer drugs.
Next Document:  The patents on glucocorticosteroids and selected new therapies for the management of asthma in child...